

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

MABTECH

RRID:SCR_013398

Type: Tool

Proper Citation

MABTECH (RRID:SCR_013398)

Resource Information

URL: <https://www.mabtech.com/>

Proper Citation: MABTECH (RRID:SCR_013398)

Description: An Antibody supplier

Synonyms: Mabtech AB

Resource Type: commercial organization

Resource Name: MABTECH

Resource ID: SCR_013398

Alternate IDs: nlx_152403, grid.452552.1

Alternate URLs: <https://ror.org/057s3rs39>

Record Creation Time: 20220129T080315+0000

Record Last Update: 20260912T195802+0000

Ratings and Alerts

No rating or validation information has been found for MABTECH.

No alerts have been found for MABTECH.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 3389 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Bae SH, et al. (2025) Rational Design of Lipid Nanoparticles for Enhanced mRNA Vaccine Delivery via Machine Learning. *Small* (Weinheim an der Bergstrasse, Germany), 21(8), e2405618.

Meng X, et al. (2025) Metabolic rewiring controlled by HIF-1 α tunes IgA-producing B-cell differentiation and intestinal inflammation. *Cellular & molecular immunology*, 22(1), 54.

Perez-Penco M, et al. (2025) The antitumor activity of TGF β -specific T cells is dependent on IL-6 signaling. *Cellular & molecular immunology*, 22(1), 111.

West EJ, et al. (2025) A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(7), 1243.

Leko V, et al. (2025) Utilization of primary tumor samples for cancer neoantigen discovery. *Journal for immunotherapy of cancer*, 13(1).

Ji S, et al. (2025) Large-scale transcript variants dictate neoepitopes for cancer immunotherapy. *Science advances*, 11(5), eado5600.

Wang C, et al. (2025) Generalization of neoantigen-based tumor vaccine by delivering peptide-MHC complex via oncolytic virus. *EMBO molecular medicine*, 17(5), 1118.

Saidoune F, et al. (2025) Enhanced TLR7-dependent production of type I interferon by pDCs underlies pandemic chilblains. *The Journal of experimental medicine*, 222(7).

Kawakita T, et al. (2025) ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4 $^{+}$ and CD8 $^{+}$ T-cell responses and neutralizing antibody induction. *Journal of virology*, 99(5), e0229024.

Agarwal R, et al. (2025) Identification of immunogenic and cross-reactive chikungunya virus epitopes for CD4 $^{+}$ T cells in chronic chikungunya disease. *Nature communications*, 16(1), 5756.

Maine CJ, et al. (2025) Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers. *Nature communications*, 16(1), 456.

Ma Q, et al. (2025) Immunogenicity of HIV-1 Env mRNA and Env-Gag VLP mRNA Vaccines in Mice. *Vaccines*, 13(1).

Shan X, et al. (2025) Robust and Long-Lasting Immunity and Protection in Mice Induced by Lipopolyplex-Delivered mRNA Vaccines Expressing the Prefusion Protein of Respiratory Syncytial Virus. *Vaccines*, 13(1).

Vargas-Montes M, et al. (2025) T-cell activation of *Toxoplasma gondii* positive donors by maltodextrin nanoparticles formulated with killed *Toxoplasma gondii*. *BMC infectious*

diseases, 25(1), 279.

Ao D, et al. (2025) A promising mRNA vaccine derived from the JN.1 spike protein confers protective immunity against multiple emerged Omicron variants. *Molecular biomedicine*, 6(1), 13.

Ansaryan S, et al. (2025) Multimodal Nanoplasmonic and Fluorescence Imaging for Simultaneous Monitoring of Single-Cell Secretory and Intracellular Dynamics. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 12(16), e2415808.

Zhang Y, et al. (2025) Programmable Stapling Peptide Based on Sulfonium as Universal Vaccine Adjuvants for Multiple Types of Vaccines. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 12(11), e2409567.

Liang X, et al. (2025) mRNA vaccines with RBD mutations have broad-spectrum activity against SARS-CoV-2 variants in mice. *NPJ vaccines*, 10(1), 7.

Banar M, et al. (2025) A novel broad-spectrum bacteriophage cocktail against methicillin-resistant *Staphylococcus aureus*: Isolation, characterization, and therapeutic potential in a mastitis mouse model. *PloS one*, 20(1), e0316157.

Yi D, et al. (2025) Chimeric hemagglutinin and M2 mRNA vaccine for broad influenza subtype protection. *NPJ vaccines*, 10(1), 113.